


# Building Success Together from Knowledge to Innovation

Scientific Pre-Conference Presented by EPION and CCEIP



**Hilton Toronto Airport Hotel**  
5875 Airport Rd  
Mississauga, ON L4V 1N1



**Scientific Pre-Conference:**  
May 15 | 10:00 - 16:30

[help4psychosis.ca/event/epion-conference-2017](http://help4psychosis.ca/event/epion-conference-2017)

The Early Psychosis Intervention Ontario Network (EPION) is a network of people who provide EPI services to individuals who have experienced psychosis and their family members. EPION currently includes over 50 programs and satellite partners across Ontario. The network facilitates collaboration between EPI sites, particularly emerging sites in need of training and established sites with resources and expertise. EPION is funded by the Ministry of Health and Long-Term Care. For more information, visit <http://help4psychosis.ca/> or join the EPION group on EENet Connect here: <http://www.eenetconnect.ca/g/the-epion-group>.

# Scientific Pre-Conference Session

EPION and the Canadian Consortium for Early Intervention in Psychosis (CCEIP) are partnering to offer a special scientific pre-conference session for psychiatrists, psychologists, clinicians and program leadership.

## At the end of this day participants will be able to:

1. Apply new clinical tools developed specifically for early phase psychosis intervention
2. Identify solutions to barriers in consideration of the integration of clinical tools into everyday workflow.
3. Identify clients who would benefit from a documented formal assessment of:
  - Relapse Risk – *Ashok Malla*
  - Appropriate Antipsychotic Therapy – *Ofer Agid*
  - Medication Side Effects – *Phil Tibbo*
  - Client Acceptance – *Howard Margoese*

## REGISTER EARLY FOR THIS SESSION. SPACE IS LIMITED.

**\$175** SCIENTIFIC PRE-CONFERENCE  
**SESSION  
REGISTRATION**

### Fee includes:

- Lunch
- Refreshments
- Session materials
- Clinical tools

CCEIP is a national organization of clinicians and researchers working within early intervention psychosis programs across Canada. Together, we are dedicated to improving the standards of care for early phase psychosis clients by enhancing training, improving services and collaborating on research activities.

**MONDAY**

**May 15, 2017 | 10:00 - 16:30**

With questions contact:

**CAROLE LEM**

Conference Registrar

[info@epion.ca](mailto:info@epion.ca)

[epion2017.eventbrite.ca](http://epion2017.eventbrite.ca)

[Click to Register](#)

# Abstract

An important objective of the CCEIP is to provide clinically relevant solutions that improve client care. The CCEIP has recently created clinical tools that address three gaps in early phase psychosis care: relapse risk assessment, monitoring of antipsychotic side effects, and decision support for selection of antipsychotics. This scientific conference will discuss the need, development, and finally review the tools themselves in an interactive manner. The aim is to have these point-of-care tools incorporated into everyday work flow, including Electronic Medical Record (EMR) integration.

While relapse is considered an almost inevitable event in the course of psychotic disorders, it does have enormous consequences for the client, his/her family, and society. Importantly, relapse rates can be minimized. The CCEIP Relapse Risk Assessment in Early Phase Psychosis questionnaire is an evidence-based tool developed for the prediction of relapse in early psychosis.

Physicians today are faced with the critical issue on how to find the best antipsychotic match for a given person at a particular moment along the early phase psychosis clinical trajectory. The CCEIP Decision-Support Tool, developed from algorithm research, will assist clinicians in evaluating treatment options based on individual client factors. This decision-support tool is also integrated into a clinical order set developed for the electronic medical record. Successful antipsychotic treatment can be complicated by both metabolic and motor side effects. Clinicians as a whole are not as vigilant at monitoring metabolic side effects as is recommended by practice guidelines. The CCEIP Antipsychotic Side Effect Monitoring tool assists clinicians in the screening for and monitoring of both metabolic and motor side effects of antipsychotics.

**MONDAY**

**May 15, 2017 | 10:00 - 16:30**

With questions contact:

**CAROLE LEM**  
Conference Registrar

[info@epion.ca](mailto:info@epion.ca)  
[epion2017.eventbrite.ca](http://epion2017.eventbrite.ca)

[Click to Register](#)

# Agenda

9:15 AM – 10:00 AM	<b>Registration and Continental Breakfast</b>	
10:00 AM – 10:05 AM	<b>Welcome</b>	<b>Chiachen Cheng</b>
10:05 AM – 10:20 AM	<b>CCEIP Introduction</b>	
10:20 AM – 10:40 AM	<b>Clinical Tool Use in Psychiatry</b>	<b>Phil Tibbo</b>
10:40 AM – 11:40 AM	<p><b>Tool Presentation #1: Relapse Risk Assessment</b></p> <ul style="list-style-type: none"> <li>• Interactive Discussion: <i>Assessing relapse risk</i></li> <li>• Impetus for the tool</li> <li>• Client and family focus group results</li> <li>• Case example demonstrating the tool</li> </ul>	
11:40 AM – 12:30 PM	<p><b>Tool Presentation #2: Client Engagement in Medication Acceptance</b></p> <ul style="list-style-type: none"> <li>• Interactive Discussion: <i>Strategies for gaining client acceptance</i></li> <li>• Impetus for the tool</li> <li>• Case example demonstrating the tool</li> </ul>	
12:30 PM – 1:15 PM	<b>LUNCH</b>	
1:15 PM – 2:15 PM	<p><b>Tool Presentation #3: Antipsychotic Treatment Selection</b></p> <ul style="list-style-type: none"> <li>• Interactive Discussion: <i>Individualized client factors</i></li> <li>• Impetus for the tool</li> <li>• Case example demonstrating the tool (electronic format)</li> <li>• Introduction of clinical order set for initiation of antipsychotic treatment</li> </ul>	
2:15 PM – 3:15 PM	<p><b>Tool Presentation #4: Monitoring Antipsychotic Side Effects</b></p> <ul style="list-style-type: none"> <li>• Video: Best practices for assessing side effects</li> <li>• Case example demonstrating the tool</li> <li>• Interactive Discussion: <i>Implementing protocols for monitoring side effects</i></li> </ul>	
3:15 PM – 3:45 PM	<b>Closing Remarks</b>	

# Speakers



## Ofer Agid, MD, FRCPC

### Staff Psychiatrist / Clinician Scientist

Schizophrenia Program, Centre for Addiction and Mental Health (CAMH) / University of Toronto

Dr. Ofer Agid is a clinician, researcher, and Staff Psychiatrist and a Clinician Scientist in the Schizophrenia Program at the Centre for Addiction and Mental Health in Toronto. His research focuses on psychopharmacology in schizophrenia, specifically early response to antipsychotic medications and early predictors of response. He is also an Associate Professor at the University of Toronto.



## Chiachen Cheng, MD, FRCPC, MPH

### Child & Adolescent, Adult Psychiatrist / Physician Researcher

First Place Clinic & Regional Resource Centre / St. Joseph's Care Group, Thunder Bay

Dr. Cheng is a clinician, researcher, and Co-Chair of EPION. Her research has examined program implementation and development, fidelity to EPI standards, evaluation of EPI training for healthcare workers, delivery of EPI services in rural and remote regions, and pathways to care among vulnerable populations. She is also an Assistant Professor at the Northern Ontario School of Medicine and Research Scientist at the Centre for Addiction and Mental Health.



## Ashok Malla, MD, FRCPC

### Director / Professor

Prevention and Early Intervention Program for Psychoses (PEPP-Montreal) / McGill University

Dr. Malla is a clinician, researcher, and holds a Tier 1 Canada Research Chair in Early Psychosis. His research focuses on the early phases of psychotic disorders, such as schizophrenia, and on prevention and early intervention of these severe illnesses. He is an international leader in the development of comprehensive programs for, and research in, early intervention in psychosis.



## Howard Margolese, MD, CM, MSc, FRCPC

### Medical Director

Early Psychosis and Schizophrenia Spectrum Program (EPSSP) / McGill University

Dr. Margolese is a clinician, researcher, and Medical Director of the McGill University Health Center Early Psychosis and Schizophrenia Spectrum Program. His research focuses on drug-induced movement disorders, pharmacotherapy of schizophrenia, and adverse effects of psychotropic medications. Dr. Margolese is also program director of the McGill RCPSC Clinical Pharmacology residency program.



## Philip Tibbo, MD, FRCPC

### Director / Co-Director

Nova Scotia Early Psychosis Program / Nova Scotia Psychosis Research Unit

Dr. Tibbo is a clinician, researcher, and President of the Canadian Consortium for Early Intervention in Psychosis (CCEIP). His research focuses on psychosis/schizophrenia in the areas of neuroimaging (MRS, DTI), genetics, and non-pharmacological treatment options for schizophrenia. Dr. Tibbo is also a Professor at Dalhousie University and Adjunct Professor at the University of Alberta.